Gliomas are a group of brain tumors that arise from glial cells, a type of support cell of the central nervous system, or CNS, which comprises the brain and spinal cord. They make up about one-quarter of all tumors that start in the brain (primary brain tumors), occurring in about 6.6 per 100,000 people every year. They also account for more than 80% of all malignant, or cancerous, brain tumors.
Read moreTreatment for gliomas, a diverse group of tumors that form in the brain and spinal cord, can involve a variety of approaches, including surgery, radiation therapy, and chemotherapy, as well as a range of supportive treatments.
Read more
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH…
The U.S. Food and Drug Administration (FDA) has granted fast track status to zotiraciclib (ZTR/TG02) — an oral medication that targets pathways in the body…
Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tinostamustine, a treatment candidate from Purdue Pharma that aims to extend…
Enrollment has begun in the second part of a clinical trial testing safusidenib, an experimental oral treatment, as a maintenance therapy for high-grade IDH1-mutant astrocytoma,…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in…
